{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:30:55Z","timestamp":1781976655664,"version":"3.54.5"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270827, 81500690, 82170805, 82201238"],"award-info":[{"award-number":["82270827, 81500690, 82170805, 82201238"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hypertension is a common adverse event after systemic glucocorticoid therapy. Previous studies have suggested that blood pressure (BP) regulation is related to serum calcium. However, whether serum calcium affects the risk of glucocorticoid-induced hypertension remains understudied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used data from thyroid-associated ophthalmopathy (TAO) patients who completed a course of intravenous methylprednisolone (IVMP). Patients with high BP at baseline, a history of hypertension, and missing data were excluded. Glucocorticoid-induced hypertension was defined as systolic BP (SBP) \u2265 140 mmHg or diastolic BP (DBP) \u2265 90 mmHg during follow-up. Multivariate logistic regression and generalized additive models were used to investigate the associations between serum calcium and glucocorticoid-induced hypertension. Bar charts were used to compare the SBP and DBP fluctuations between patients with and without hypocalcemia. After accounting for missing data, all analyses were repeated in the imputed cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Serum calcium was negatively correlated with glucocorticoid-induced hypertension after adjusting for covariates with p-value &amp;lt; 0.1 (including age, body mass index, SBP, and DBP). For each 0.1 mmol\/L increase in serum calcium, the OR (95% CI) was 0.61 (0.39, 0.95). Furthermore, a nonlinear relationship was observed, with an inflection point at 2.10 mmol\/L. After the serum calcium level was converted into a categorical variable, hypocalcemia was positively associated with glucocorticoid-induced hypertension (OR = 3.26, 95% CI = 1.11\u20139.53). Patients with hypocalcemia exhibited significantly greater SBP fluctuations than patients without hypocalcemia (p &amp;lt; 0.05). These results were stable when adjusting for confounders and in the analyses of the imputed cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Hypocalcemia was associated with glucocorticoid-induced hypertension in TAO patients. Further research is needed to confirm these findings in larger populations and to investigate whether calcium supplementation before glucocorticoid therapy may reduce such risk.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1548953","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:10:34Z","timestamp":1744344634000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Negative association between serum calcium and glucocorticoid-induced hypertension in thyroid-associated ophthalmopathy patients treated with methylprednisolone"],"prefix":"10.3389","volume":"16","author":[{"given":"Ling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin K. L.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 Disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101387","article-title":"Graves\u2019 disease: Epidemiology, genetic and environmental risk factors and viruses","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj9867","article-title":"Abrogation of self-tolerance by misfolded self-antigens complexed with MHC class II molecules","volume":"8","author":"Jin","year":"2022","journal-title":"Sci Adv"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0311093","DOI":"10.1371\/journal.pone.0311093","article-title":"Linsitinib inhibits IGF-1-induced cell proliferation and hyaluronic acid secretion by suppressing PI3K\/Akt and ERK pathway in orbital fibroblasts from patients with thyroid-associated ophthalmopathy","volume":"19","author":"Lee","year":"2024","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: A randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S2213-8587(18)30021-4","article-title":"Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 x 2 factorial, double-blind, randomised controlled trial","volume":"6","author":"Rajendram","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.024","article-title":"Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies","volume":"128","author":"Winn","year":"2021","journal-title":"Ophthalmology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14290","article-title":"Sirolimus versus mycophenolate mofetil for triple immunosuppression in thyroid eye disease patients with recent-onset intractable diplopia: A prospective comparative case series","volume":"51","author":"Lai","year":"2023","journal-title":"Clin Exp Ophthalmol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.160377","article-title":"Rapamycin improves Graves\u2019 orbitopathy by suppressing CD4+ cytotoxic T lymphocytes","volume":"8","author":"Zhang","year":"2023","journal-title":"JCI Insight"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19102918","article-title":"Blood pressure profile and N-terminal-proBNP dynamics in response to intravenous methylprednisolone pulse therapy of severe graves\u2019 Orbitopathy","volume":"19","author":"Miskiewicz","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa209","article-title":"Glucocorticoid use is associated with an increased risk of hypertension","volume":"60","author":"Costello","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0370-z","article-title":"Views on glucocorticoid therapy in rheumatology: the age of convergence","volume":"16","author":"Buttgereit","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1994.tb00855.x","article-title":"Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy","volume":"236","author":"Conn","year":"1994","journal-title":"J Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)11911-8","article-title":"Prospective Studies C. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-006-9013-y","article-title":"Acute myocardial infarction during high-dose methylprednisolone therapy for Graves\u2019 ophthalmopathy","volume":"28","author":"Owecki","year":"2006","journal-title":"Pharm World Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/2047487316681174","article-title":"Circulating active serum calcium reduces the risk of hypertension","volume":"24","author":"Kunutsor","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12011-013-9646-3","article-title":"The relationship between serum calcium level, blood lipids, and blood pressure in hypertensive and normotensive subjects who come from a normal university in east of China","volume":"153","author":"Yao","year":"2013","journal-title":"Biol Trace Elem Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03330330039033","article-title":"Reduction of blood pressure with calcium supplementation in young adults","volume":"249","author":"Belizan","year":"1983","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001059.pub5","article-title":"Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems","volume":"10","author":"Hofmeyr","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010037.pub4","article-title":"Calcium supplementation for prevention of primary hypertension","volume":"1","author":"Cormick","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12011-013-9805-6","article-title":"Association of serum calcium and hypertension among adolescents aged 12-17 years in the rural area of Northeast China","volume":"155","author":"Sun","year":"2013","journal-title":"Biol Trace Elem Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.719165","article-title":"Association between serum calcium and the prevalence of hypertension among US adults","volume":"8","author":"Hua","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1161\/HYPERTENSIONAHA.116.07806","article-title":"Body mass index predicts 24-hour urinary aldosterone levels in patients with resistant hypertension","volume":"68","author":"Dudenbostel","year":"2016","journal-title":"Hypertension"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00209.2022","article-title":"Vasoactive mediators of hypertension in obesity","volume":"325","author":"Ghanim","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6644","article-title":"Association between baseline blood pressure and the incidence of lenvatinib-induced hypertension in patients with thyroid cancer","volume":"12","author":"Shibutani","year":"2023","journal-title":"Cancer Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c150052","article-title":"Calcium homeostasis in health and in kidney disease","volume":"6","author":"Moe","year":"2016","journal-title":"Compr Physiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/0895-7061(95)00149-J","article-title":"Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension","volume":"8","author":"Sato","year":"1995","journal-title":"Am J Hypertens"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/nu11051112","article-title":"Mechanisms involved in the relationship between low calcium intake and high blood pressure","volume":"11","author":"Villa-Etchegoyen","year":"2019","journal-title":"Nutrients"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198905000-00012","article-title":"Low-calcium diet increases blood pressure and alters peripheral but not central angiotensin II binding sites in rats","volume":"7","author":"Baksi","year":"1989","journal-title":"J Hypertens"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.13.3.219","article-title":"Effect of oral calcium on blood pressure response in salt-loaded borderline hypertensive patients","volume":"13","author":"Saito","year":"1989","journal-title":"Hypertension"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198907000-00005","article-title":"The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume","volume":"7","author":"Whitworth","year":"1989","journal-title":"J Hypertens"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.23.13357","article-title":"Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension","volume":"96","author":"Wallerath","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B39","article-title":"Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans","volume":"14","author":"Williamson","year":"1996","journal-title":"J Hypertens Suppl"},{"key":"B40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ecl.2011.01.010","article-title":"How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids","volume":"40","author":"Ong","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0282-9","article-title":"Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events","volume":"74","author":"Fardet","year":"2014","journal-title":"Drugs"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.11.2_pt_2.i42","article-title":"Contribution of vasopressin in dexamethasone-induced hypertension in rats","volume":"11","author":"Iijima","year":"1988","journal-title":"Hypertension"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199009000-00006","article-title":"Increased sensitivity to noradrenaline in glucocorticoid-treated rats: the effects of indomethacin and desipramine","volume":"8","author":"Russo","year":"1990","journal-title":"J Hypertens"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.19.6.567","article-title":"Pressor responsiveness in corticosteroid-induced hypertension in humans","volume":"19","author":"Pirpiris","year":"1992","journal-title":"Hypertension"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.601922","article-title":"Dexamethasone promotes hypertension by allele-specific regulation of the human angiotensinogen gene","volume":"290","author":"Pandey","year":"2015","journal-title":"J Biol Chem"},{"key":"B46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1042\/cs0650037","article-title":"Urinary prostaglandin E2 and kallikrein excretion in glucocorticoid hypertension in rats","volume":"65","author":"Handa","year":"1983","journal-title":"Clin Sci (Lond)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.niox.2004.01.008","article-title":"Dexamethasone lacks effect on blood pressure in mice with a disrupted endothelial NO synthase gene","volume":"10","author":"Wallerath","year":"2004","journal-title":"Nitric Oxide"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1042\/CS20080178","article-title":"Dexamethasone decreases neuronal nitric oxide release in mesenteric arteries from hypertensive rats through decreased protein kinase C activation","volume":"117","author":"Aras-Lopez","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1161\/01.hyp.23.1.25","article-title":"Glucocorticoid increases angiotensin II type 1 receptor and its gene expression","volume":"23","author":"Sato","year":"1994","journal-title":"Hypertension"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199405000-00003","article-title":"Increased expression of vascular angiotensin II type 1A receptor gene in glucocorticoid-induced hypertension","volume":"12","author":"Sato","year":"1994","journal-title":"J Hypertens"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/endo.130.6.1597163","article-title":"Regulation of hepatic angiotensinogen synthesis and secretion by steroid hormones","volume":"130","author":"Klett","year":"1992","journal-title":"Endocrinology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.25.3.343","article-title":"Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle","volume":"25","author":"Fishel","year":"1995","journal-title":"Hypertension"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1548953\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:10:35Z","timestamp":1744344635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1548953\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":52,"alternative-id":["10.3389\/fendo.2025.1548953"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1548953","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"article-number":"1548953"}}